US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
US7700603B2
(en)
|
2003-12-15 |
2010-04-20 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
TWI332005B
(en)
|
2005-06-14 |
2010-10-21 |
Schering Corp |
Aspartyl protease inhibitors
|
US8722708B2
(en)
|
2005-06-14 |
2014-05-13 |
Merck Sharp & Dohme Inc. |
Substituted isoindolines as aspartyl protease inhibitors
|
ES2537898T3
(es)
|
2005-10-25 |
2015-06-15 |
Shionogi & Co., Ltd. |
Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
|
US8168641B2
(en)
|
2006-06-12 |
2012-05-01 |
Schering Corporation |
Aspartyl protease inhibitors
|
JP5383483B2
(ja)
|
2007-04-24 |
2014-01-08 |
塩野義製薬株式会社 |
アルツハイマー症治療用医薬組成物
|
JP5383484B2
(ja)
|
2007-04-24 |
2014-01-08 |
塩野義製薬株式会社 |
環式基で置換されたアミノジヒドロチアジン誘導体
|
CA2711655C
(en)
*
|
2008-01-18 |
2013-03-05 |
Eisai R&D Management Co., Ltd. |
Condensed aminodihydrothiazine derivative
|
AU2009239535A1
(en)
|
2008-04-22 |
2009-10-29 |
Schering Corporation |
Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
|
US8637504B2
(en)
|
2008-06-13 |
2014-01-28 |
Shionogi & Co., Ltd. |
Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
|
US8501733B2
(en)
*
|
2008-07-28 |
2013-08-06 |
Eisai R&D Management Co., Ltd. |
Spiroaminodihydrothiazine derivatives
|
CA2736130C
(en)
*
|
2008-09-11 |
2014-01-14 |
Amgen Inc. |
Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
|
RU2503681C2
(ru)
*
|
2008-09-30 |
2014-01-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Новое конденсированное производное аминодигидротиазина
|
KR20110076965A
(ko)
*
|
2008-09-30 |
2011-07-06 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규한 축합 아미노 디하이드로티아진 유도체
|
JPWO2010047372A1
(ja)
|
2008-10-22 |
2012-03-22 |
塩野義製薬株式会社 |
Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
|
AR077277A1
(es)
*
|
2009-07-09 |
2011-08-17 |
Lilly Co Eli |
Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
|
GB0912778D0
(en)
|
2009-07-22 |
2009-08-26 |
Eisai London Res Lab Ltd |
Fused aminodihydro-oxazine derivatives
|
GB0912777D0
(en)
|
2009-07-22 |
2009-08-26 |
Eisai London Res Lab Ltd |
Fused aminodihydropyrimidone derivatives
|
AR077328A1
(es)
|
2009-07-24 |
2011-08-17 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
|
EP2485590B1
(en)
|
2009-10-08 |
2015-01-07 |
Merck Sharp & Dohme Corp. |
Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
|
US8563543B2
(en)
|
2009-10-08 |
2013-10-22 |
Merck Sharp & Dohme Corp. |
Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
US8569310B2
(en)
|
2009-10-08 |
2013-10-29 |
Merck Sharp & Dohme Corp. |
Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
|
UA108363C2
(uk)
|
2009-10-08 |
2015-04-27 |
|
Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
|
US20120238557A1
(en)
*
|
2009-11-13 |
2012-09-20 |
Shionogi & Co., Ltd. |
Aminothiazine or aminooxazine derivative having amino linker
|
US8870950B2
(en)
|
2009-12-08 |
2014-10-28 |
Mitral Tech Ltd. |
Rotation-based anchoring of an implant
|
JPWO2011070781A1
(ja)
|
2009-12-09 |
2013-04-22 |
塩野義製薬株式会社 |
置換アミノチアジン誘導体
|
US7964594B1
(en)
|
2009-12-10 |
2011-06-21 |
Hoffmann-La Roche Inc. |
Amino oxazine derivatives
|
US20120245155A1
(en)
*
|
2009-12-11 |
2012-09-27 |
Shionogi & Co., Ltd. |
Fused heterocyclic compound having amino group
|
UA103272C2
(xx)
|
2009-12-11 |
2013-09-25 |
Ф. Хоффманн-Ля Рош Аг |
2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2$2-амино-5,5-дифтор-5,6-дигидро-4h-оксазины как ингибиторы bace1 и/или bace2
|
BR112012013854A2
(pt)
|
2009-12-11 |
2019-09-24 |
Shionogi & Co |
derivados de oxazina.
|
SG181431A1
(en)
|
2009-12-31 |
2012-07-30 |
Novartis Ag |
Pyrazine derivatives and their use in the treatment of neurological disorders
|
US8497264B2
(en)
|
2010-03-15 |
2013-07-30 |
Amgen Inc. |
Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
|
US8883782B2
(en)
|
2010-03-15 |
2014-11-11 |
Amgen Inc. |
Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
|
US8673894B2
(en)
|
2010-05-07 |
2014-03-18 |
Hoffmann-La Roche Inc. |
2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
|
CN102666507B
(zh)
|
2010-07-13 |
2014-09-17 |
诺华股份有限公司 |
噁嗪衍生物及其在治疗神经病症中的用途
|
US8921363B2
(en)
|
2010-08-05 |
2014-12-30 |
Amgen Inc. |
Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
|
JP5816630B2
(ja)
|
2010-10-29 |
2015-11-18 |
塩野義製薬株式会社 |
ナフチリジン誘導体
|
WO2012057247A1
(ja)
|
2010-10-29 |
2012-05-03 |
塩野義製薬株式会社 |
縮合アミノジヒドロピリミジン誘導体
|
EP2643325A1
(en)
|
2010-11-23 |
2013-10-02 |
Amgen Inc. |
Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
|
GB201100181D0
(en)
|
2011-01-06 |
2011-02-23 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
MX2013008111A
(es)
|
2011-01-12 |
2013-10-30 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos.
|
EA024059B1
(ru)
|
2011-01-13 |
2016-08-31 |
Новартис Аг |
Гетероциклические производные и их применение в лечении неврологических расстройств
|
GB201101139D0
(en)
|
2011-01-21 |
2011-03-09 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
BR112013016241A2
(pt)
|
2011-01-21 |
2016-07-12 |
Eisai R&D Man Co Ltd |
composto, e, método para fabricar um composto
|
GB201101140D0
(en)
*
|
2011-01-21 |
2011-03-09 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
US9346827B2
(en)
|
2011-02-07 |
2016-05-24 |
Amgen Inc. |
5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
|
US8404680B2
(en)
|
2011-02-08 |
2013-03-26 |
Hoffmann-La Roche Inc. |
N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
|
US8962859B2
(en)
|
2011-02-15 |
2015-02-24 |
Amgen Inc. |
Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
|
US8815841B2
(en)
|
2011-02-18 |
2014-08-26 |
Hoffmann-La Roche Inc. |
1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
|
WO2012138734A1
(en)
|
2011-04-07 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
WO2012138590A1
(en)
|
2011-04-07 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
US8754075B2
(en)
|
2011-04-11 |
2014-06-17 |
Hoffmann-La Roche Inc. |
1,3-oxazines as BACE1 and/or BACE2 inhibitors
|
WO2012147763A1
(ja)
|
2011-04-26 |
2012-11-01 |
塩野義製薬株式会社 |
オキサジン誘導体およびそれを含有するbace1阻害剤
|
BR112014004181A2
(pt)
|
2011-08-22 |
2017-06-13 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
|
EP2751116B1
(en)
|
2011-08-31 |
2016-10-12 |
Pfizer Inc |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
WO2013044092A1
(en)
|
2011-09-21 |
2013-03-28 |
Amgen Inc. |
Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
|
UA113538C2
(xx)
|
2012-01-26 |
2017-02-10 |
|
Фторметил-5,6-дигідро-4h-$1,3]оксазини
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
JO3143B1
(ar)
|
2012-04-03 |
2017-09-20 |
Lilly Co Eli |
مركبات تتراهيدرو بيرولو ثيازين
|
EP2841423B1
(en)
*
|
2012-04-27 |
2016-11-30 |
Eisai R&D Management Co., Ltd. |
Method for producing 5-(difluoromethyl)pyrazine-2-carboxilic acid and production intermediate thereof
|
JP6110937B2
(ja)
|
2012-05-04 |
2017-04-05 |
ファイザー・インク |
APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
WO2014015125A1
(en)
|
2012-07-19 |
2014-01-23 |
Eisai R&D Management Co., Ltd. |
Fused aminodihydrothiazine derivative salts and uses thereof
|
GB201212871D0
(en)
*
|
2012-07-20 |
2012-09-05 |
Eisai Ltd |
Novel compounds
|
JP2015529239A
(ja)
|
2012-09-20 |
2015-10-05 |
ファイザー・インク |
アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
WO2014065434A1
(en)
|
2012-10-24 |
2014-05-01 |
Shionogi & Co., Ltd. |
Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
|
EP2912041B1
(en)
|
2012-10-26 |
2016-12-14 |
Eli Lilly and Company |
Tetrahydropyrrolothiazine derivatives as bace inhibitors
|
US9725469B2
(en)
|
2012-11-15 |
2017-08-08 |
Amgen, Inc. |
Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
|
EP2931731A1
(en)
|
2012-12-11 |
2015-10-21 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
EP2935282A1
(en)
|
2012-12-19 |
2015-10-28 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
US9309263B2
(en)
|
2013-01-29 |
2016-04-12 |
Amgen Inc. |
Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
|
WO2014125394A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
|
US9233981B1
(en)
*
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
WO2014134341A1
(en)
|
2013-03-01 |
2014-09-04 |
Amgen Inc. |
Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
EP2964644B1
(en)
|
2013-03-08 |
2018-12-26 |
Amgen, Inc. |
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
TWI593692B
(zh)
*
|
2013-03-12 |
2017-08-01 |
美國禮來大藥廠 |
四氫吡咯并噻嗪化合物
|
CA2900433C
(en)
|
2013-04-11 |
2021-06-22 |
F. Hoffmann-La Roche Ag |
Bace1 inhibitors
|
JO3318B1
(ar)
*
|
2013-06-18 |
2019-03-13 |
Lilly Co Eli |
مثبطات bace
|
US9096615B2
(en)
|
2013-07-30 |
2015-08-04 |
Amgen Inc. |
Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
|
TWI684452B
(zh)
|
2014-03-14 |
2020-02-11 |
美國禮來大藥廠 |
胺基噻嗪化合物
|
MD20160105A2
(ro)
|
2014-04-10 |
2017-03-31 |
Pfizer Inc. |
2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
|
WO2016022724A1
(en)
|
2014-08-08 |
2016-02-11 |
Amgen Inc. |
Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
TWI570127B
(zh)
|
2014-09-15 |
2017-02-11 |
美國禮來大藥廠 |
結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
|
TWI599358B
(zh)
*
|
2014-09-16 |
2017-09-21 |
美國禮來大藥廠 |
組合療法
|
KR102524217B1
(ko)
*
|
2014-10-10 |
2023-04-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
축합 아미노디하이드로티아진 유도체의 의약 조성물
|
TWI574969B
(zh)
*
|
2015-01-30 |
2017-03-21 |
美國禮來大藥廠 |
甲苯磺酸鹽
|
AR103680A1
(es)
*
|
2015-02-23 |
2017-05-24 |
Lilly Co Eli |
Inhibidores selectivos de bace1
|
US9938266B2
(en)
|
2015-03-19 |
2018-04-10 |
Eli Lilly And Company |
Selective BACE1 inhibitors
|
AR104241A1
(es)
*
|
2015-04-29 |
2017-07-05 |
Lilly Co Eli |
Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
|
WO2017024180A1
(en)
|
2015-08-06 |
2017-02-09 |
Amgen Inc. |
Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
WO2017051276A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
EP3353182A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
|
JP2018534251A
(ja)
|
2015-09-24 |
2018-11-22 |
ファイザー・インク |
Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US10065952B2
(en)
|
2015-10-30 |
2018-09-04 |
Neurocrine Biosciences, Inc. |
Valbenazine salts and polymorphs thereof
|
MD3377488T2
(ro)
|
2015-11-19 |
2023-02-28 |
Incyte Corp |
Compuși heterociclici ca imunomodulatori
|
EP3383493B1
(en)
|
2015-12-04 |
2021-02-17 |
Merck Sharp & Dohme Corp. |
Carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use
|
EP3390361B1
(en)
*
|
2015-12-17 |
2022-03-16 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
SG11201805300QA
(en)
|
2015-12-22 |
2018-07-30 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
(S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
|
TW201740954A
(zh)
*
|
2016-03-16 |
2017-12-01 |
美國禮來大藥廠 |
組合療法
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
US20170342060A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CA3028685A1
(en)
|
2016-06-20 |
2017-12-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US20180016260A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3500296A1
(en)
*
|
2016-08-18 |
2019-06-26 |
Eli Lilly and Company |
Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
AR110470A1
(es)
|
2016-10-21 |
2019-04-03 |
Lilly Co Eli |
Terapia de combinación para tratar la enfermedad de alzheimer
|
SG10201913049QA
(en)
*
|
2016-10-27 |
2020-02-27 |
Eisai R&D Man Co Ltd |
Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
|
EP3555086B1
(en)
|
2016-12-15 |
2021-09-01 |
Amgen Inc. |
1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
|
ES2910367T3
(es)
|
2016-12-15 |
2022-05-12 |
Amgen Inc |
Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso
|
CA3047287A1
(en)
|
2016-12-15 |
2018-06-21 |
Amgen Inc. |
Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
|
MX2019007101A
(es)
|
2016-12-15 |
2019-12-16 |
Amgen Inc |
Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
|
JP7149272B2
(ja)
|
2016-12-15 |
2022-10-06 |
アムジエン・インコーポレーテツド |
β-セクレターゼ阻害剤としてのチアジン誘導体および使用方法
|
US20180179179A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
HRP20221216T1
(hr)
|
2016-12-22 |
2022-12-23 |
Incyte Corporation |
Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
|
ES2934230T3
(es)
|
2016-12-22 |
2023-02-20 |
Incyte Corp |
Derivados de benzooxazol como inmunomoduladores
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN107892697B
(zh)
*
|
2016-12-26 |
2020-11-03 |
郑州泰基鸿诺医药股份有限公司 |
一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物
|
CA3051829A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
JP7250006B2
(ja)
|
2017-09-21 |
2023-03-31 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
|
KR20200066661A
(ko)
|
2017-10-10 |
2020-06-10 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
FI3774791T3
(fi)
|
2018-03-30 |
2023-03-21 |
Incyte Corp |
Heterosyklisiä yhdisteitä immunomodulaattoreina
|
CN112752756A
(zh)
|
2018-05-11 |
2021-05-04 |
因赛特公司 |
作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
|
CN112805031A
(zh)
|
2018-07-24 |
2021-05-14 |
卫材R&D管理有限公司 |
阿尔茨海默病的治疗及预防方法
|
BR112021000019A2
(pt)
|
2018-08-15 |
2021-04-06 |
Neurocrine Biosciences Inc. |
Métodos para administração de certos inibidores de vmat2
|
CN109748878A
(zh)
*
|
2019-01-21 |
2019-05-14 |
江苏中旗科技股份有限公司 |
一种甲磺草胺关键中间体苯连三唑啉酮衍生物的制备方法
|
TW202115059A
(zh)
|
2019-08-09 |
2021-04-16 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之鹽
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
AU2020357514A1
(en)
|
2019-09-30 |
2022-04-07 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
WO2021096849A1
(en)
|
2019-11-11 |
2021-05-20 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
US11760756B2
(en)
|
2020-11-06 |
2023-09-19 |
Incyte Corporation |
Crystalline form of a PD-1/PD-L1 inhibitor
|
IL302590A
(en)
|
2020-11-06 |
2023-07-01 |
Incyte Corp |
Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|